Vogenx Inc Common Stock (VOGX)

Vogenx Inc Common Stock (VOGX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $216M; returns 1 day -8.5%, 1 week +20.1%.

Vogenx, Inc. (VOGX) is a clinical-stage biopharmaceutical company that debuted on the Nasdaq in August 2026. The company is primarily focused on developing novel oral therapeutics for serious metabolic and gastrointestinal disorders. Its lead product candidate, mizagliflozin, is a minimally absorbed, selective SGLT1 (sodium-glucose transporter 1) inhibitor.

Groups VOGX belongs to

• Clinical Stage Biotech
• Recent IPOs
• Biotechnology
• Biopharmaceutical
• Clinical Stage
• Metabolic Disorders
• Gastroenterology
• Life Sciences
• Healthcare

VOGX financial model: income statement, cash flow and balance sheet